- Home
- FATE vs DTIL Comparison
FATE vs DTIL Comparison
Compare FATE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | DTIL |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 128.8M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FATE | DTIL |
|---|---|---|
| Price | $1.05 | $6.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $4.10 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.4M | 273.0K |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,646,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.05 | $48.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $3.53 |
| 52 Week High | $1.94 | $8.82 |
Technical Indicators
Market Signals| Indicator | FATE | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 78.99 |
| Support Level | $0.96 | $3.96 |
| Resistance Level | $1.16 | $8.82 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | -0.05 | 0.25 |
| Stochastic Oscillator | 2.11 | 78.48 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.